Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
A Single-arm Clinical Trial to Explore the Safety and Efficacy of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to verify the safety and clinical benefit of pulsed electric field (PEF) treatment of advanced or unresectable esophageal squamous cell carcinoma patients.
The main questions it aims to answer are:
- Safety and feasibility of PEF treatment of patients with advanced or unresectable esophageal squamous cell carcinoma.
- Locoregional control of ablated lesions and quality of life assessment.
- Local and peripheral immunoregulation effect.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sara Xu
- Phone Number: +86 021 52230973
- Email: info@energenxmedical.com
Study Locations
-
-
-
Shanghai, China
- Shanghai Chest Hospital
-
Contact:
- Zhigang Li, M.D., Ph.D.
- Phone Number: 021-22200000
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 20 years or older when signing the informed consent form.
- Able to provide written informed consent, and understand and follow the study requirements and assessment schedule.
- Screening period tumor patients ECOG performance status score of 0 or 1.
Laboratory test data within 7 days before the planned PEF treatment date during the screening period must meet the following standards.
- Neutrophil count (ANC) ≥1500 cells/mm3
- Platelet count ≥100,000 cells/mm3
- Hemoglobin ≥9 g/dL or ≥5.6 mmol/L
- Serum total bilirubin ≤ 1.5 x ULN.
- Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to undergo additional pregnancy testing during the study.
Exclusion Criteria:
- Subjects with active respiratory tract infection who need antibiotic or antiviral treatment;
- Patients with locally advanced ESCC whose tumors can be surgically removed by the investigator or can be potentially cured by radical chemoradiotherapy according to the judgment of local investigators.
- Patients with esophageal lesions that severely invade adjacent organs (esophagus/bronchus or esophagus/aorta) and are assessed as high-risk esophageal leakage/fistula by the investigator.
- Evidence of complete esophageal obstruction that is not suitable for treatment, and gastroscopy cannot be performed.
- Patients with a history of esophageal stent implantation for esophageal obstruction;
- Patients with a history of gastrointestinal bleeding in the past 4 weeks, or gastroscopy indicates a high risk of tumor ulcer bleeding.
- Patients with obstruction caused by anastomotic stenosis without esophageal primary lesions after previous esophageal cancer surgery.
- Patients with active leptomeningeal disease or brain metastasis.
- Any active malignant tumor within 5 years before screening.
- Subjects have undergone metal implantation surgery such as esophageal stents and airway stents. Or the patient has an implantable cardioverter-defibrillator, pacemaker or other implantable electronic device.
- Patients with positive HIV test.
- Subjects are currently participating in other research clinical trials;
- Subjects who are considered by the investigator to have other high-risk conditions and are not suitable for gastroscopy and surgery;
- Subjects who have adverse events that have not yet returned to baseline or stable levels due to previous anti-tumor treatment, except for adverse events that do not pose safety risks (such as hair loss and abnormal values of specific laboratory tests)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PEF treatment
One group prospective clinical
|
PEF energy delivery via endoscope
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of PEF treatment
Time Frame: 1 month
|
evaluate the rate of AEs/SAEs associated with instrument-related/or surgical procedures within 30 days of PEF treatment
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Esophageal Diseases
- Carcinoma
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Carcinoma, Squamous Cell
Other Study ID Numbers
Other Study ID Numbers
- EC-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.